Morgan Stanley
AVIR icon

Morgan Stanley’s Atea Pharmaceuticals AVIR Stock Holding History

Morgan Stanley’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.93M Buy
731,020
+74,945
+11% +$344K ﹤0.01% 4306
2025
Q4 		$2.34M Buy
656,075
+205,511
+46% +$653K ﹤0.01% 4700
2025
Q3 		$1.31M Sell
450,564
-93,704
-17% -$320K ﹤0.01% 5029
2025
Q2 		$1.96M Buy
544,268
+88,924
+20% +$265K ﹤0.01% 4718
2025
Q1 		$1.36M Sell
455,344
-111,696
-20% -$349K ﹤0.01% 4843
2024
Q4 		$1.9M Buy
567,040
+78,141
+16% +$260K ﹤0.01% 4732
2024
Q3 		$1.64M Buy
488,899
+121,359
+33% +$440K ﹤0.01% 4766
2024
Q2 		$1.22M Sell
367,540
-37,099
-9% -$138K ﹤0.01% 4843
2024
Q1 		$1.63M Sell
404,639
-410,673
-50% -$1.61M ﹤0.01% 4697
2023
Q4 		$2.49M Buy
815,312
+550,220
+208% +$1.67M ﹤0.01% 4803
2023
Q3 		$795K Sell
265,092
-164,404
-38% -$559K ﹤0.01% 4930
2023
Q2 		$1.61M Sell
429,496
-47,689
-10% -$179K ﹤0.01% 4557
2023
Q1 		$1.6M Buy
477,185
+37,951
+9% +$154K ﹤0.01% 4586
2022
Q4 		$2.11M Sell
439,234
-57,746
-12% -$292K ﹤0.01% 4425
2022
Q3 		$2.83M Buy
496,980
+104,464
+27% +$800K ﹤0.01% 4174
2022
Q2 		$2.79M Sell
392,516
-36,105
-8% -$246K ﹤0.01% 4278
2022
Q1 		$3.1M Sell
428,621
-214,121
-33% -$1.45M ﹤0.01% 4171
2021
Q4 		$5.75M Buy
642,742
+200,056
+45% +$3.12M ﹤0.01% 3570
2021
Q3 		$15.5M Sell
442,686
-346,662
-44% -$9.62M ﹤0.01% 2373
2021
Q2 		$17M Buy
789,348
+731,027
+1,253% +$22M ﹤0.01% 2334
2021
Q1 		$3.6M Sell
58,321
-48,266
-45% -$3.26M ﹤0.01% 3750
2020
Q4 		$4.45M Buy
+106,587
New +$3.44M ﹤0.01% 3385

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley's AVIR Position: Q1 2026 in Review

Morgan Stanley increased its Atea Pharmaceuticals (AVIR) stake by 11% in Q1 2026, buying an estimated $344K and bringing the position to 731,020 shares worth $3.93M. The position accounts for ﹤0.01% of the portfolio, ranked #4306.

Morgan Stanley first reported a position in AVIR in Q4 2020 and has held it in 22 quarters since. The position peaked at $17M in Q2 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Morgan Stanley held 731,020 shares of Atea Pharmaceuticals worth $3.93M as of Q1 2026.
  • Morgan Stanley bought 74,945 Atea Pharmaceuticals shares in Q1 2026, an estimated $344K.
  • Atea Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4306 holding.
  • Morgan Stanley first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Morgan Stanley's Atea Pharmaceuticals position peaked at $17M in Q2 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.